The devil’s in the e-detail: what HCPs really want from youOverview Communication; we all do it, it is a critical part of effective business practice and in this Share XThe devil’s in the e-detail: what HCPs really want from youhttps://pharmaphorum.com/digital/the-devils-in-the-e-detail-what-hcps-really-want-from-you/
Bayer applies artificial intelligence to its pharmacovigilance systemsBayer is looking to accelerate its patient safety data monitoring by using artificial intelligence in a move it Share XBayer applies artificial intelligence to its pharmacovigilance systemshttps://pharmaphorum.com/news/bayer-artificial-intelligence-pharmacovigilance/
Bayer plans filings for prostate cancer drug darolutamideBayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped Share XBayer plans filings for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-plans-filings-for-prostate-cancer-drug-darolutamide/
Novartis, Bayer consider appeal as court says Avastin can be used in AMDEngland’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in Share XNovartis, Bayer consider appeal as court says Avastin can be used in AMDhttps://pharmaphorum.com/news/novartis-bayer-consider-appeal-as-court-says-avastin-can-be-used-in-amd/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
LEO Pharma acquires Bayer’s dermatology unitDanish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer’s global Share XLEO Pharma acquires Bayer’s dermatology unithttps://pharmaphorum.com/news/leo-pharma-acquires-bayers-dermatology-unit/
Bayer hits back at Netflix medical device documentaryBayer has issued a robust defence of Essure after the birth control implant was featured in The Bleeding Share XBayer hits back at Netflix medical device documentaryhttps://pharmaphorum.com/news/bayer-netflix-essure-safety/
Raising the bar in liver cancer therapypharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
